Drug Topics: Most Read Stories From 2024

Know Labs Announces Wearable, Non-Invasive Continuous Glucose Monitor

As the most read story throughout the entirety of 2024, Drug Topics readers were quick to get the scoop on Know Labs Inc’s newest continuous glucose monitor it announced in February. Non-invasive and wearable for all patients, the device is known as the KnowU. It’s equipped with real-time computing power as well as artificial intelligent and machine learning capabilities.

Top read Drug Topics stories from the year 2024 | image credit: Celt Studio / stock.adobe.com

Breakthrough Vaccine for Chronic Hepatitis B Enters First In-Human Trial

Earlier this year, researchers began the very first in-human clinical trial of TherVacB, a novel therapeutic vaccine designed to cure chronic hepatitis B. The vaccine is designed to activate CD4 T-cells and potentially offer a cure for hepatitis B, which impacts over 300 million patients across the world. While some vaccines of the sort have been proposed in recent history, none have provided antiviral efficacy.

Phase 1/2 Trial of Investigational Herpes Zoster Vaccine Candidate Underway

Continuing with clinical vaccine trials, Dynavax began its phase 1/2 clinical trial for Z-1018, an investigational vaccine candidate for the prevention of herpes zoster (shingles). Trial participants 50 to 69 years old entered the trial, allowing researchers to test the safety, tolerability, and immunogenicity of the vaccine. A total of 440 participants would be enrolled in the trial across 3 study sites in Australia.

FDA Grants Clearance to twiist Automated Insulin Delivery System for T1D

One of the more unique FDA actions in the past year, the next story focused on the twiist Automated Insulin Delivery System—the first drug delivery system that measures both insulin volume and flow with each micro-dose. The new tech will create an even greater opportunity for patients with type 1 diabetes to stay on top of their insulin levels.

FDA Grants Breakthrough Therapy Designation to LSD-Based Treatment for Generalized Anxiety Disorder

What may be even more outside of the box for specific individuals, the FDA granted a breakthrough therapy designation for using LSD to treat generalized anxiety disorder. Lysergide d-tartrate (MM120), also known as LSD, is a semi-synthetic hallucinogen that has been commonly criticized for its negative effects and connotations throughout history. However, its new indication is a promising sign for patients suffering from anxiety and serves as an opportunity to change the public’s perspective on LSD and hallucinogens as a whole.

Pharmacy practice is always changing. Stay ahead of the curve: Sign up for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips, straight to your inbox.